Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of WT2725 in advanced solid tumors
jRCT2080222290Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Nov 2013
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of wt2725 in Non-hematologic malignancy, sponsored by Sumitomo Pharma. Primary endpoints: Safety and tolerability of WT2725 and Maximum tolerated dose (MTD). Started Nov 2013; status: completed.
02
Drugs
wt2725
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080222290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222290.